Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Hervé Avet-Loiseau, Jill Corre, Michel Attal

Blood (2022) 139 (18): 2747–2757.

https://doi.org/10.1182/blood.2021014635

Published: 2022

Includes: Supplemental data

Journal Articles

Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM)

Aurore Perrot, Valérie Lauwers-Cances, Cyrille Touzeau, Olivier Decaux, Cyrille Hulin, Magaret Macro, Anne-Marie Stoppa, Marie Lorraine Chretien, Lionel Karlin, Clara Mariette, Caroline Jacquet, Murielle Roussel, Coralie Guillemot, Laure Devlamynck, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal

Blood (2021) 138 (Supplement 1): 464.

https://doi.org/10.1182/blood-2021-146040

Published: 2021

Journal Articles

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier, Laurent Garderet, Martine Escoffre-Barbe, Clara Mariette, Lotfi Benboubker, Denis Caillot, Cécile Sonntag, Cyrille Touzeau, Jehan Dupuis, Philippe Moreau, Xavier Leleu, Thierry Facon, Benjamin Hébraud, Jill Corre, Michel Attal

Blood (2021) 138 (2): 113–121.

https://doi.org/10.1182/blood.2021010744

Published: 2021

Journal Articles

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-134538

Published: 2020

Journal Articles

The Discriminatory Ability of the R-ISS Is Equivalent to the ISS in a Large Cohort of Newly Diagnosed Multiple Myeloma (NDMM) Patients

Anaïs Schavgoulidze, Valerie Lauwers-Cances, Aurore Perrot, Herve Avet-Loiseau, Jill Corre, PharmD, PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136996

Published: 2020

Journal Articles

Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)

Murielle Roussel, MD, Benjamin Hebraud, MD, Cyrille Hulin, MD, Xavier Leleu, MD PhD, Thierry Facon, MD, Eileen Boyle, MD PhD, Cyrille Touzeau, MD PhD, Brigitte Pegourie, MD, Aurore Perrot, MD PhD, Anne-Marie Stoppa, MD, Jean-Pierre Marolleau, MD PhD, Philippe Moreau, MD, Herve Avet-Loiseau, MD PhD, Laure Devlamynck, Valerie Lauwers-Cances, MD, Michel Attal, MD PhD

Blood (2019) 134 (Supplement_1): 3159.

https://doi.org/10.1182/blood-2019-123184

Published: 2019

Journal Articles

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Blood (2018) 132 (23): 2456–2464.

https://doi.org/10.1182/blood-2018-06-858613

Published: 2018

Includes: Supplemental data

Journal Articles

Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial

Hervé Avet-Loiseau, MD PhD, Valerie Lauwers-Cances, MD, Jill Corre, PharmD, PhD, Philippe Moreau, MDPhD, Michel Attal, MD PhD, Nikhil Munshi, MD

Blood (2017) 130 (Supplement 1): 435.

https://doi.org/10.1182/blood.V130.Suppl_1.435.435

Published: 2017

Journal Articles

Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)

Blood (2017) 130 (Supplement 1): 398.

https://doi.org/10.1182/blood.V130.Suppl_1.398.398

Published: 2017

Journal Articles

Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Krd Phase II Study

Murielle Roussel, MD, Valerie Lauwers-Cances, MD, Nelly Robillard, PhD, Karim Belhadj, MD, Thierry Facon, MD PhD, Laurent Garderet, MD, Martine Escoffre, MD, Brigitte Pegourie, MD, Lotfi Benboubker, MD PhD, Denis Caillot, Cecile Fohrer, MD, Philippe Moreau, Xavier Leleu, Herve Avet-Loiseau, MD PhD, Michel Attal

Blood (2016) 128 (22): 1142.

https://doi.org/10.1182/blood.V128.22.1142.1142

Published: 2016

Journal Articles

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Blood (2015) 126 (25): 2713–2719.

https://doi.org/10.1182/blood-2015-06-650242

Published: 2015

Includes: Supplemental data

Journal Articles

Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial

Blood (2015) 126 (23): 191.

https://doi.org/10.1182/blood.V126.23.191.191

Published: 2015

Journal Articles

Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

Michel Attal, Valerie Lauwers-Cances, MD, Cyrille Hulin, MD, Thierry Facon, Denis Caillot, Martine Escoffre, Bertrand Arnulf, Margaret MACRO, MD, Karim Belhadj, MD, Laurent Garderet, MD, Murielle Roussel, MD, Claire Mathiot, MD, Herve Avet-Loiseau, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, jean Luc Harousseau, Philippe Moreau

Blood (2015) 126 (23): 391.

https://doi.org/10.1182/blood.V126.23.391.391

Published: 2015

Journal Articles

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

Blood (2015) 125 (13): 2095–2100.

https://doi.org/10.1182/blood-2014-07-587964

Published: 2015

Journal Articles

in Multiple Myeloma, High-Risk Features Are Modulated By Other Chromosomal changes : A Large Snparray IFM Study

Jill Corre, PharmD, PhD, Benjamin Hebraud, MD, Florence Magrangeas, PhD, Valérie Lauwers-Cances, MD, Marie-Lorraine Chretien, MD, Stephane Minvielle, PhD, Hervé Avet-Loiseau

Blood (2014) 124 (21): 641.

https://doi.org/10.1182/blood.V124.21.641.641

Published: 2014

Journal Articles

Prognostic Factors Affecting Progression Free Survival For Multiple Myeloma Patients Receiving Lenalidomide Maintenance After Autologous Transplantation. Follow-Up Analysis Of The IFM 2005-02 Trial

Gerald Marit, MD, Valérie Lauwers-Cances, MD, Denis Caillot, MD, Thierry Facon, MD, Cyrille Hulin, MD, Philippe Moreau, MD, Claire Mathiot, MD, Murielle Roussel, MD, Catherine Payen, MD, Pascale Olivier, PharmD, Hervé Avet-Loiseau, MD, PhD, Michel Attal, MD

Blood (2013) 122 (21): 3312.

https://doi.org/10.1182/blood.V122.21.3312.3312

Published: 2013

Journal Articles

Lenalidomide Maintenance After Stem-Cell Transplantation For Multiple Myeloma: Follow-Up Analysis Of The IFM 2005-02 Trial

Michel Attal, MD, Valérie Lauwers-Cances, MD, Gérald Marit, MD, Denis Caillot, MD, Thierry Facon, MD, Cyrille Hulin, MD, Philippe Moreau, MD, Claire Mathiot, MD, Murielle Roussel, MD, Catherine Payen, MD, Pascale Olivier, PharmD, Hervé Avet-Loiseau, MD, PhD

Blood (2013) 122 (21): 406.

https://doi.org/10.1182/blood.V122.21.406.406

Published: 2013

Journal Articles

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia

Sarah Bertoli, Emilie Bérard, Françoise Huguet, Anne Huynh, Suzanne Tavitian, François Vergez, Sophie Dobbelstein, Nicole Dastugue, Véronique Mansat-De Mas, Eric Delabesse, Eliane Duchayne, Cécile Demur, Audrey Sarry, Valérie Lauwers-Cances, Guy Laurent, Michel Attal, Christian Récher

Blood (2013) 121 (14): 2618–2626.

https://doi.org/10.1182/blood-2012-09-454553

Published: 2013

Includes: Supplemental data

Journal Articles

1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients

Blood (2012) 120 (21): 933.

https://doi.org/10.1182/blood.V120.21.933.933

Published: 2012

Journal Articles

Long-Term Maintenance with Lenalidomide Improves Progression Free Survival In Myeloma Patients with High-Risk Cytogenetics: An IFM Study

Blood (2010) 116 (21): 1944.

https://doi.org/10.1182/blood.V116.21.1944.1944

Published: 2010

NARROW

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

The Discriminatory Ability of the R-ISS Is Equivalent to the ISS in a Large Cohort of Newly Diagnosed Multiple Myeloma (NDMM) Patients

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial

Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial

Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

in Multiple Myeloma, High-Risk Features Are Modulated By Other Chromosomal changes : A Large Snparray IFM Study

Prognostic Factors Affecting Progression Free Survival For Multiple Myeloma Patients Receiving Lenalidomide Maintenance After Autologous Transplantation. Follow-Up Analysis Of The IFM 2005-02 Trial

Lenalidomide Maintenance After Stem-Cell Transplantation For Multiple Myeloma: Follow-Up Analysis Of The IFM 2005-02 Trial

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia

1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients

Long-Term Maintenance with Lenalidomide Improves Progression Free Survival In Myeloma Patients with High-Risk Cytogenetics: An IFM Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only